Literature DB >> 29948463

Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer.

Tatsuhiko Naito1, Masao Osaki2, Megumi Ubano2, Mami Kanzaki2, Yoshikazu Uesaka2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29948463     DOI： 10.1007/s10072-018-3465-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

1.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Authors:  Tanya J Williams; David R Benavides; Kelly-Ann Patrice; Josep O Dalmau; Alexandre Leon Ribeiro de Ávila; Dung T Le; Evan J Lipson; John C Probasco; Ellen M Mowry
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

2.  Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.

Authors:  Shigeaki Suzuki; Nobuhisa Ishikawa; Fumie Konoeda; Nobuhiko Seki; Satoshi Fukushima; Kikuko Takahashi; Hisashi Uhara; Yoshikazu Hasegawa; Shinichiro Inomata; Yasushi Otani; Kenji Yokota; Takashi Hirose; Ryo Tanaka; Norihiro Suzuki; Makoto Matsui
Journal:  Neurology       Date:  2017-08-18       Impact factor: 9.910

3.  Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

Authors:  Justin C Kao; Bing Liao; Svetomir N Markovic; Christopher J Klein; Elie Naddaf; Nathan P Staff; Teerin Liewluck; Julie E Hammack; Paola Sandroni; Heidi Finnes; Michelle L Mauermann
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

4.  Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

Authors:  James Larkin; Bartosz Chmielowski; Christopher D Lao; F Stephen Hodi; William Sharfman; Jeffrey Weber; Karijn P M Suijkerbuijk; Sergio Azevedo; Hewei Li; Daniel Reshef; Alexandre Avila; David A Reardon
Journal:  Oncologist       Date:  2017-05-11

5.  Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer.

Authors:  Lidia Sabater; Romana Höftberger; Anna Boronat; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240
  5 in total
  6 in total

1.  Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.

Authors:  Christine A Garcia; Alex El-Ali; Tanya J Rath; Lydia C Contis; Vikram Gorantla; Jan Drappatz; Diwakar Davar
Journal:  J Immunother Cancer       Date:  2018-08-31       Impact factor: 13.751

2.  Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review.

Authors:  Laure Thouvenin; Timothée Olivier; Giuseppe Banna; Alfredo Addeo; Alex Friedlaender
Journal:  Ther Adv Drug Saf       Date:  2021-03-29

Review 3.  Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention.

Authors:  Benxia Zhang; Xue Li; Tao Yin; Diyuan Qin; Yue Chen; Qizhi Ma; Pei Shu; Yongsheng Wang
Journal:  J Oncol       Date:  2022-01-18       Impact factor: 4.375

Review 4.  Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature.

Authors:  Chiara Demichelis; Andrea Balestra; Caterina Lapucci; Angela Zuppa; Stefano G Grisanti; Valeria Prada; Giampaola Pesce; Ilaria Grasso; Paola Queirolo; Angelo Schenone; Luana Benedetti; Marina Grandis
Journal:  Neurol Sci       Date:  2020-08-11       Impact factor: 3.307

5.  Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19.

Authors:  Kenta Osawa; Atsuhiko Sugiyama; Akiyuki Uzawa; Shigeki Hirano; Tatsuya Yamamoto; Masahiko Nezu; Nobuyuki Araki; Hiroki Kano; Satoshi Kuwabara
Journal:  Intern Med       Date:  2022-02-01       Impact factor: 1.282

Review 6.  Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.

Authors:  Sophie L Duong; Harald Prüss
Journal:  Neurotherapeutics       Date:  2022-01-18       Impact factor: 6.088
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.